Ulrich S. Koch

Adam Bruce is a seasoned executive with extensive experience in the pharmaceutical and biotech sectors. Currently serving as Chief Executive Officer, Founder, and Board Member at TikoMed AB since March 2002, Adam Bruce has been instrumental in driving the company's vision and growth. Additionally, Adam Bruce holds the position of Chairman at Abarceo Pharma, focusing on innovative solutions for Type 2 Diabetes. Ownership of WaveSeven AB since 2014 further underscores entrepreneurial aspirations. Adam Bruce's previous roles include Working Chairman and CEO at TikoMed AB during its early years, contributing significantly to its development. Academic credentials include studies at Lund University and participation in various executive education programs.